



US006037368A

United States Patent [19]

Podos et al.

[11] **Patent Number:** 6,037,368[45] **Date of Patent:** Mar. 14, 2000[54] **8-ISO- PROSTAGLANDINS FOR GLAUCOMA THERAPY**[75] Inventors: Steven M. Podos, Tenaflly, N.J.;
Thomas W. Mittag, Pleasantville, N.Y.;
Bernard Becker, University City, Mo.[73] Assignee: Mount Sinai School of Medicine, New
York, N.Y.

[21] Appl. No.: 09/073,552

[22] Filed: May 6, 1998

Related U.S. Application Data[63] Continuation of application No. 08/853,803, May 9, 1997,
abandoned.[51] Int. Cl.⁷ A61K 31/215; A61K 31/19

[52] U.S. Cl. 514/530; 514/573; 514/913

[58] Field of Search 514/530, 573,
514/913[56] **References Cited****U.S. PATENT DOCUMENTS**4,132,847 1/1979 Kuhla et al. .
4,599,353 7/1986 Bito .
5,151,444 9/1992 Ueno et al. .
5,173,507 12/1992 DeSantis et al. .5,208,256 5/1993 Ueno .
5,262,437 11/1993 Chan .
5,462,968 10/1995 Woodward .
5,476,872 12/1995 Garst et al. .
5,565,492 10/1996 DeSantis et al. .
5,578,618 11/1996 Stjernschantz .
5,631,287 5/1997 Schneider 514/530**FOREIGN PATENT DOCUMENTS**

9411002 5/1994 WIPO .

OTHER PUBLICATIONSPodos et al., Mar. 15, 1998, Invest. Ophthalmol. Visual Sci.
39(4):S258, abstract 1178-B57 (title on the Internet several
months earlier, believed to be in 1998).Wang et al., Mar. 15, 1997, Invest. Ophthalmol. Visual Sci.
38(4):S815, abstract 3795-B396.*Primary Examiner*—Zohreh Fay*Attorney, Agent, or Firm*—Bakerbotts LLP[57] **ABSTRACT**

The present invention relates to the use of 8-iso prostaglan-
dins and their derivatives for decreasing intraocular
pressure, for example in the treatment of glaucoma It is
based, at least in part, on the discovery that 8-iso prostag-
landin E₂ effectively decreased intraocular pressure by a
trabecular meshwork outflow mechanism.

21 Claims, No Drawings

10074438-00400